Lymphedema Leads to Fat Deposition in Muscle and Decreased Muscle/Water Volume After Liposuction: A Magnetic Resonance Imaging Study

Mattias Hoffner, MD,1,2 Pernilla Peterson, PhD,3 Sven Månsson, PhD,3 and Håkan Brorson, MD, PhD1,4

Abstract

Background: Lymphedema leads to adipose tissue deposition. Water–fat magnetic resonance imaging (MRI) can quantify and localize fat and water. The presence of excess fat and excess water/muscle in the subfascial compartment of the lymphedematous limb has not been investigated before. The aim of this study was to investigate epifascial and subfascial fat and water contents in patients with chronic lymphedema before and after liposuction.

Methods and Results: Seven patients with arm lymphedema and six with leg lymphedema were operated on. The limbs were examined with water–fat MRI before liposuction (baseline) and at five time points. Complete reduction of the excess limb volumes was achieved. The excess epifascial fat was evident in the edematous limbs and a drop was seen following surgery. There were differences in excess water at all time points. At 1 year there was a decrease in excess water. Excess subfascial fat was seen in the edematous limbs at all time points. Subfascial excess water/muscle did not show any differences after surgery. However, starting from 3 months there was less subfascial water/muscle compared with baseline.

Conclusions: Subfascial fat in the lymphedematous limbs did not change. In contrast, the water in the subfascial compartment was reduced over time, which may represent a decrease of muscle volume after treatment due to less mechanical load after liposuction. Using water–fat MRI-based fat quantification, the fat and water contents may be quantified and localized in the various compartments in lymphedema.

Keywords: lymphedema, liposuction, adipose tissue, fat, MRI, water–fat imaging

Introduction

Lymphedema is a chronic, complex, and multifaceted condition that has major physical, psychological, and social implications for the quality of life of patients suffering from it.1,2 Any disruption of the lymph flow due to disease or iatrogenic damage (surgery, radiotherapy, or trauma) can result in failure to transport lymph back to the blood circulation, resulting in a lymphedema.

Stagnation of the lymph fluid circulation will, if left untreated, enhance tissue changes such as excess adipose tissue and excess fibrosis deposition in the affected limb. Adipose tissue deposition in lymphedema probably occurs because the fat cell is not simply a container of fat, but is an endocrine organ and a cytokine-activated cell, and chronic inflammation plays a role here.3 Earlier reports have attributed the excess adipose tissue to a slow lymph flow accelerating lipogenesis and fat deposition.4 This process is enhanced by the transformation of macrophages into adipocytes.5,6 Subsequently, subcutaneous lymphedema becomes firm due to pinocytosis of white blood cells and activation of fibroblasts, which will increase the connective tissue component of the lymphedema.7,8 More recent research focuses on inflammation and upregulation of fat differentiation markers as an alternative course of adipose tissue deposition.9-12 Furthermore, lymph fluid stasis drives adipose-derived stem cells toward adipogenic differentiation.13

Lymphedema remains a significant clinical problem with 20% of women developing the condition following treatment.

1Department of Clinical Sciences, Lund University, Malmö, Sweden.
2Department of Surgery, Blekinge Hospital, Karlskrona, Sweden.
3Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
4Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Malmö, Sweden.

© Hoffner et al., 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
for breast cancer.\textsuperscript{14,15} In spite of recent sentinel node dissection in breast cancer treatment, still 5.6\% are affected.\textsuperscript{15} In addition, up to one third of women report leg lymphedema following gynecological cancer treatment.\textsuperscript{16} Patients with lymphedema are susceptible to erysipelas and the concomitant inflammation may increase adipose tissue deposition.\textsuperscript{17}

Since lymphedema evolves from a soft pitting state to an irreversible fatty and fibrotic state, which also may show pitting, it is important to define the different stages in lymphedema. One definition has been introduced by the International Society of Lymphology: “Stage 0 (or Ia) which refers to a latent or sub-clinical condition where swelling is not yet evident despite impaired lymph transport, subtle changes in tissue fluid/composition, and changes in subjective symptoms. It may exist months or years before overt edema occurs (Stages I–III). Stage I represents an early accumulation of fluid that is relatively high in protein content (e.g., in comparison with ‘venous’ edema), which subsides with limb elevation. Pitting may occur. An increase in various proliferating cells may also be seen. Stage II signifies that limb elevation alone rarely reduces tissue swelling and pitting is manifest. Late in Stage II, the limb may or may not pit as excess fat and fibrosis supervene. Stage III encompasses lymphostatic elephantiasis where pitting can be absent and trophic skin changes such as acanthosis, further deposition of fat and fibrosis, and warty overgrowths have developed.”\textsuperscript{18}

A lymphedema, diagnosed at an early stage, is treated conservatively (i.e., combined physical therapy using daily bandaging until pitting disappears, followed by measurement for made-to-measure compression garments) to reduce the edema.\textsuperscript{19,30} For a late stage lymphedema this treatment will be unsuccessful because it is in an irreversible state with adipose tissue deposition and only surgical treatment will reduce the excess volume completely.\textsuperscript{20,21}

Depending on the lymphedema stage, the lymphedema will not only have a varying subjective and objective impact on patients’ quality of life, but also an impact on choosing the appropriate treatment method (i.e., conservative treatment, microsurgical procedures, liposuction in combination with conservative treatment). To obtain accurate information concerning the relations of the lymphedema components (excess fat hypertrophy, edema) there is a need for reliable noninvasive diagnostic imaging techniques since no consensus on their use exists.\textsuperscript{22}

There are different imaging techniques, each with their own advantages and disadvantages, giving insights into the tissue changes due to lymphedema (i.e., ultrasonography, computed tomography, dual-energy X-ray absorptiometry, and magnetic resonance imaging [MRI]), but they usually focus on the dermal and subcutaneous levels.

The presence of excess epifascial fat has previously been investigated using computed tomography and dual-energy X-ray absorptiometry.\textsuperscript{20,21} However, these techniques are not suitable for localized measurement of the much lower fat concentrations expected in the subfascial compartment. Using water–fat MRI for fat quantification, the fat and water contents may be both quantified and localized.\textsuperscript{23} This method separates the acquired MRI images into water and fat images,\textsuperscript{24,25} which are used to quantify the percentage fat fraction (FF). After consideration and correction of various sources of bias, the approach is robust\textsuperscript{26} and has been validated against independent measurements.\textsuperscript{27,28} This method has mainly been used for liver and muscle applications.\textsuperscript{23,29}

The potential presence of excess fat and excess water/muscle in the subfascial compartment before and after liposuction of the lymphedematous limb has not yet been investigated.

The aim of this study was to use water–fat MRI to investigate epifascial and subfascial fat and water contents in patients with chronic arm or leg lymphedema before, and at five time points after liposuction.

### Materials and Methods

#### Study design and subjects

Seven patients with arm lymphedema and six patients with leg lymphedema who were scheduled to receive liposuction of the edematous limb participated in this study (Table 1). All arm lymphedema patients occurred following breast cancer treatment. Of the six leg lymphedema patients, three had been treated for cancer (two with uterus cancer and one with synovial sarcoma in the groin) and three had primary lymphedema (one male and two females). All patients had been treated conservatively before liposuction and were wearing compression garments daily. Thus, there was no or minimal pitting when performing the pitting test.\textsuperscript{21,30} In addition, 10 healthy volunteers were recruited as controls (median age 30 years; first and third quartiles [1q–3q] 28–44; 7 right-handed, 3 left-handed).

The study was approved by the Ethics of Human Investigation Committee at Lund University (LU 2006/503 and 2011/45) and informed consent was obtained from all subjects. The procedures were in accordance with the Helsinki Declaration of 2013.

#### Plethysmography

Limb volumes were measured with water plethysmography at six time points (baseline, 2 weeks, 1 month, 3 months, 6 months, and 1 year).\textsuperscript{19,30,31} For plethysmography, all patients were measured, except for one at 1 year due to recurrence of the breast cancer. The healthy controls were not measured.

### Table 1. Characteristics of the Study Population (Median [1q–3q])

|                | Arms         | Legs         |
|----------------|--------------|--------------|
| Number of patients | 7            | 6            |
| Excess volume preoperatively (mL) | 1345 (865 to 1548) | 3733 (2920 to 5618) |
| Excess volume postoperatively at 1 year (mL) | -180 (-374 to 243)  | -430 (-513 to -74)  |
| Age at liposuction (years) | 62 (60 to 71)  | 35 (31 to 52)  |
| Duration of lymphedema (years) | 6.0 (3.5 to 8.5)  | 9.0 (4.5 to 14)  |
The healthy and edematous limbs of patients were examined with water–fat MRI before liposuction (baseline) and at five time points (4 days, 1 month, 3 months, 6 months, and 1 year) after liposuction. At 6 months, 3 patients could not be measured due to technical problems. At 1 year, 12 patients were measured and 1 could not be measured because of recurrence of the breast cancer. Both forearms of the healthy volunteers were examined with MRI at one time point, and their right forearm was imaged a second time with repositioning to evaluate the methods repeatability. This investigation has previously been described and resulted in a high repeatability, where the 95% confidence interval of repeated measures of the percentage fat content within the subfascial compartment was within ±0.4%. Only the first of the two measurements of the right arm is used in this work.

**MRI protocol**

All MRI examinations were conducted with a 1.5 T MRI scanner (MAGNETOM Sonata; Siemens Healthcare) using a small flex coil (arms) and large flex coil (legs). Arms were imaged separately, whereas both legs were imaged together. Imaging was centered 10 cm distally of the humeral epicondyle (arms), or 16 cm distally of the femoral condyle (legs).

A multiecho gradient-echo sequence was used to image three 5-mm slices with 5-mm interslice gap and 1.6×1.6 mm² resolution. Eight echo times (first TE = 1.83 ms, interecho time = 2.47 ms) were acquired with TR = 600, flip angle 10°, bandwidth = 815 Hz/pixel, field of view = 400×200 mm², number of averages = 4, and acquisition time = 5 minutes and 6 seconds. The images were reconstructed offline in MATLAB (R2013a; MathWorks, Natick, MA) to separate water and fat images using a combination of magnitude and complex data with correction for B0 inhomogeneity, a single T2*, and multiple fat peaks. From the separated water and fat images, the FF was calculated in each image voxel as FF = F/(F+W). The water fraction (WF) was estimated as WF = W/(W+F).

In each image slice, polygonal regions of interest (ROI) were manually drawn covering the epifascial and subfascial compartments (excluding bone and bone marrow). In each ROI, the total water and fat volumes were calculated as the voxel volume multiplied by the sum of the WW or FF of each voxel within that ROI. Thus, for each limb of each patient four measures were obtained within a 15-mm section of the limb: the subfascial water volume, the subfascial fat volume, the epifascial water volume, and the epifascial fat volume. Note that the subfascial water volume includes both edematous and muscle tissue.

**Statistical analyses**

All statistical testing were carried out in MATLAB (R2013a; MathWorks). The excess volume was defined as the difference between the lymphedematous limb and the healthy limb in the patient group, and the difference between dominant and the nondominant limb in the volunteer group.

At each time point, the relative excess volume (percent) was estimated as (volume edematous limb – volume healthy limb)/volume healthy limb for patients and as (volume dominant – volume nondominant)/volume nondominant arm for healthy controls. These values were compared between baseline and each postoperative time point using a Wilcoxon signed-rank test. Significant changes from baseline to postoperative time points are shown with upper asterisks in Figures 1–5.

Moreover, the Wilcoxon signed-rank test was also used to compare the edematous and healthy side (patients) at each time point. For volunteers, the dominant and nondominant arm was measured once. Significant differences between limbs are shown with lower asterisks in Figures 1–5. Medians (1q–3q) were calculated for outcomes in Table 1. The outcome of these tests was considered to show exploratory results, and therefore nominal p-values are presented without any adjustment for multiple comparisons. For all tests, p < 0.05 was considered a significant result.

**Results**

**Limb volume reduction**

Complete reduction of the excess limb volumes was achieved after liposuction in both arm and leg lymphedema patients at 1 year after surgery (Fig. 1). At baseline, significant excess limb volumes were seen in the edematous limbs. After liposuction, a drop in the excess limb volume was seen in the lymphedematous extremities resulting in a significantly lower excess limb volume at 2 weeks and 1 month postoperatively compared with baseline. At 3 months, 6 months, and 1 year no significant difference between the limbs was seen due to a normalization of the volume of the affected limbs (lower asterisks in Fig. 1). Consequently, a significantly lower excess limb volume remained for all postoperative time points compared with baseline (upper asterisks in Fig. 1).

![FIG. 1. Relative excess total limb volume (%). A significantly larger excess epifascial fat volume was seen in the edematous limbs at baseline and at 2 weeks and 1 month after surgery. No significant difference between limbs was seen at 3 months, 6 months, and 1 year after surgery (lower asterisks). A significant drop in total excess limb volumes remained for all postoperative time points compared with baseline (upper asterisks). *p < 0.05, **p < 0.01, ***p < 0.001.](image-url)
**Epifascial excess fat volume**

At baseline, a significant excess epifascial fat volume was evident in the edematous limbs (Fig. 2). As liposuction was performed subcutaneously between the skin and the muscle fascia, a significant drop in the excess fat volume was seen in the lymphedematous extremities resulting in a significantly lower excess epifascial fat volume for all time points following surgery (lower asterisks in Fig. 2). Consequently, a significantly lower excess epifascial fat volume remained for all postoperative time points compared with baseline (upper asterisks in Fig. 2). No difference in the epifascial excess fat volume was seen between the extremities in healthy controls.

**Epifascial excess water volume**

Epifascial excess water volume represents edema fluid in the epifascial compartment. During follow-up, there were significant differences between limbs in excess volumes at all time points (lower asterisks in Fig. 3) indicating that there was still a fluid component in the compartment. At 1 year there was a significant decrease compared with baseline in excess water volume (upper asterisks in Fig. 3), which may have been caused by efficient use of compression garments. No difference in the epifascial excess water volume was seen between the extremities in healthy controls.

**Subfascial excess fat volume**

A significant excess subfascial fat volume was seen in the edematous limbs at all time points (Fig. 4). For obvious reasons, liposuction is not performed in the subfascial compartment and therefore a significant difference to baseline is not displayed at any time point. No difference in the subfascial excess fat volume was seen between the extremities in healthy controls.

**Subfascial excess water/muscle volume**

During follow-up, there were no significant differences between the lymphedematous and normal extremities at any time point (Fig. 5). However, starting from 3 months there was a significantly smaller subfascial water/muscle volume compared with baseline. No difference in the subfascial excess water/muscle volume was seen between the extremities in healthy controls.

**Discussion**

Using water–fat MRI, the fat and water contents may be both quantified and localized in the various compartments in the lymphedematous limb. In this study, we show how excess fat and water/muscle volumes in lymphedema change over time in two different compartments after liposuction. Water–fat MRI cannot differentiate between muscle tissue and water using the technique presented in this article; thus, the measured excess subfascial water volume represents both edematous fluid and muscle tissue.

Healthy controls were examined to investigate any differences between the dominant and nondominant sides in a nonlymphedematous group in the various compartments. As can be seen in the figures, no such differences were found.

We noticed, starting from 3 months, a significantly smaller subfascial water volume compared with baseline (Fig. 5). The reason for this is unclear, but is most likely due to a switch from a hypertrophied muscle cell state to a normal muscle cell state caused by less mechanical load from the heavy lymphedematous extremity.21,34

Our finding of increased volume of subfascial fat in arm and leg lymphedema using a robust and validated MRI technique has not been reported in the literature, and might in the future help us acquire additional information about the evolution and symptoms connected to lymphedema.

Diagnosis of lymphedema is determined by patient history, subjective/objective symptoms, and measurement of volume differences between the affected and nonaffected limbs. In early stages of lymphedema, neither volume measurements nor physical examination will provide detailed information about the stage of lymphedema, which might have a negative impact on choosing an appropriate treatment modality.

---

**FIG. 2.** Relative excess epifascial fat volume (%). A significantly larger excess epifascial fat volume was seen in the edematous limbs at baseline. Following surgery a significantly lower excess epifascial fat volume was noted in the edematous limbs at all time points (lower asterisks). A significant drop in epifascial excess fat volume remained for all postoperative time points compared with baseline (upper asterisks). No difference in the fat volume was seen between the extremities in healthy controls. **p < 0.01, ***p < 0.001.
Although previous research done on detecting lymphedema at an early stage and at a superficial localization with tissue dielectric constant (TDC) and local or locoregional bioimpedance spectroscopy (BIS), there are discrepancies between them in assessing lymphedema. These are due to different measurement techniques and assessed tissue water components. Currently there is no scientific evidence on whether the diagnostic power of these local/locoregional BIS measurements would be better than that of the conventional and widely used BIS technique. Further development of both of these measurement techniques and correlation of results with imaging are important before translation into routine clinical practice. On the other hand, water–fat MRI not only detects superficial tissue changes, but also changes in the whole composition of the extremity. Thus, water–fat MRI can possibly be used as a supplement to BIS and TDC in standardizing these methods, and in addition to analyze deep tissue changes before and after treatment.

**Clinical aspects and the need for further investigations**

Fat quantification using water–fat MRI is a well-established technique that has been used to gain insights into the pathophysiology of metabolic diseases, including obesity, metabolic syndrome, or type 2 diabetes. The perspectives are promising, but this field of research still requires further investigations before clinical application.

Fat serves as an energy reservoir, but more importantly, since the discovery of leptin it has also been shown to play an important endocrine role influencing a variety of physiological and pathological processes, including immunity and inflammation.

**FIG. 3.** Relative excess epifascial water volume (%). A significantly larger excess epifascial water volume was seen in the edematous limbs at baseline and at all time points after surgery (lower asterisks). No significant change in the excess water volume was seen compared with baseline until after 1 year, where a smaller excess epifascial water volume was seen (upper asterisks). No difference in the water volume was seen between the extremities in healthy controls. **\( p < 0.01, \)** \( p < 0.001. \)

**FIG. 4.** Relative excess subfascial fat volume (%). A significantly larger excess volume of subfascial fat was seen in the edematous limbs at all time points. No significant change in the excess subfascial fat was seen compared with baseline at any time. No difference in the subfascial fat volume was seen between the extremities in healthy controls. *\( p < 0.05, \)** **\( p < 0.01, \)** **\( p < 0.001. \)
Fat accumulation and fibrosis in the epifascial compartment are clinical hallmarks of lymphedema. In 2012, Zampell et al. showed that lymphatic obstruction in an animal model led to a significant fat and collagen deposition. In addition, their findings of fat hypertrophy and an increased number of adipocytes suggest that the process of fat accumulation, in response to lymphatic fluid stasis, mimics the events that occur in obesity in general.

In 2009, Boettcher et al. showed that the amount of intermuscular adipose tissue (IMAT) is higher in males compared with females and, furthermore, it increases significantly with age. Compared with other fat compartments, the amount of IMAT was found to be a good predictor for insulin sensitivity, with a correlation coefficient almost equal to that of visceral adipose tissue (VAT). It seems that IMAT and VAT share an analogous pattern in distribution and association with insulin sensitivity. Excessive accumulation of IMAT (subfascial fat) is closely related to insulin resistance, and may also be linked to age, inflammation, and conditions of chronic pain. Thus, measurement of epifascial and subfascial fat deposits may also be of value for patients with chronic lymphedema and for the understanding of the underlying pathophysiological processes in fat deposition.

In this study, we did not investigate specific fat/water distribution patterns at a cellular level in the subfascial compartment (i.e., between muscle cells or within muscle cells) neither any specific patterns in the epifascial compartment. Also we cannot conclusively identify any pathophysiological effects related to changes in fat and water volumes in lymphedema. The understanding of possible fat distribution-mediated effects and the molecular mechanisms that regulate different pathophysiological conditions (i.e., insulin sensitivity, chronic pain, and proinflammatory actions) in lymphedema need to be further investigated.

**Limitations**

The study population was relatively small, including seven patients with arm lymphedema and six with leg lymphedema, thus statistical analysis was performed without differentiating between arm and leg lymphedema. Consequently, we cannot exclude that outcomes might be different for arms and legs. Also, only three cross-sections of 5 mm each (in total 15 mm) were investigated in each limb, which may not be representative for the whole limb. Water–fat MRI cannot differentiate water signals between fluid and muscle, which makes it difficult to evaluate subfascial tissue changes. Regarding controls, these were not age matched, but since each control individual is its own control (right and left arm), this may not have a significant impact on the outcome.

**Conclusion**

Using water–fat MRI-based fat quantification; the fat and water contents may be quantified and localized in the various compartments in the lymphematous limb.

This study shows that the excess volume of epifascial fat and water decreased after liposuction. Also, the excess volume of the lymphematous limbs was reduced completely when compared with the nonlymphematous limbs. Interestingly, we also found an excess volume of fat in the subfascial compartment in the lymphematous limbs that did not change over time. In contrast, the excess volume of water in the subfascial compartment was reduced over time, which may represent a decrease of muscle volume after treatment caused by less mechanical load after liposuction. The water–fat MRI can be used to study the detailed pathophysiological consequences of lymphedema as well as any possible effects after use of anti-inflammatory drugs to decrease fat deposition. It may also be used together with TDC and BIS, which analyzes superficial changes for standardization and also to study changes in deep compartments of the extremities.

**Acknowledgments**

The authors thank occupational therapist Karin Ohlin and physiotherapist Barbro Svensson at the Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Malmö, Sweden for assistance with the
plethysmography measurements. The project was supported by the Swedish Cancer Society, Stockholm, the Skåne County Council’s Research and Development Foundation, and the Scientific Committee of Blekinge County Council’s Research and Development Foundation.

Author Disclosure Statement

No competing financial interests exist.

References

1. Brorson H, Ohlin K, Olsson G, Langstrom G, Wiklund I, Svensson H. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology 2006; 39:8–25.
2. Hoffner M, Bagheri S, Hansson E, Manjer J, Troeng T, Brorson H. SF-36 shows increased quality of life following complete reduction of postmastectomy lymphedema with liposuction. Lymphat Res Biol 2017; 15:87–98.
3. Brorson H. Liposuction in lymphedema treatment. J Reconstr Microsurg 2016; 32:56–65.
4. Larsen OA, Lassen NA, Quaade F. Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 1966; 66:337–345.
5. Smahel J. Adipose tissue in plastic surgery. Ann Plast Surg 1986; 16:444–453.
6. Ryan TJ. Lymphatics and adipose tissue. Clin Dermatol 1995; 13:493–498.
7. Casley-Smith JR, Gaffney RM. Excess plasma proteins as a cause of chronic inflammation and lymphedema: Quantitative electron microscopy. J Pathol 1981; 133:243–272.
8. Gaffney RM, Casley-Smith JR. Excess plasma proteins as a cause of chronic inflammation and lymphoedema: Biochemical estimations. J Pathol 1981; 133:229–242.
9. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 2005; 37:1072–1081.
10. Zampell JC, Aschen S, Weitman ES, Yung A, Elhadad S, De Brot M, Mehrara BJ. Regulation of adipogenesis by lymphatic fluid stasis: Part I. Adipogenesis, fibrosis, and inflammation. Plast Reconstr Surg 2012; 129:825–834.
11. Ashen S, Zampell JC, Elhadad S, Weitman E, De Brot M, Mehrara BJ. Regulation of adipogenesis by lymphatic fluid stasis: Part II. Expression of adipose differentiation genes. Plast Reconstr Surg 2012; 129:838–847.
12. Rockson SG. The lymphatics and the inflammatory response: Lessons learned from human lymphedema. Lymphat Res Biol 2013; 11:117–120.
13. Levi B, Glotzbach JP, Sorkin M, Hyun J, Januszky M, Wan DC, Li S, Nelson ER, Longaker MT, Gurtner GC. Molecular analysis and differentiation capacity of adipose-derived stem cells from lymphedema tissue. Plast Reconstr Surg 2013; 132:580–589.
14. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: A three-year follow-up study. QJM 2005; 98:343–348.
15. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis. Lancet Oncol 2013; 14:500–515.
16. Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M, Aoyagi Y, Ohba Y, Okamoto K, Kato H. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010; 119:60–64.
17. Lee D, Piller N, Hoffner M, Manjer J, Brorson H. Liposuction of postmastectomy arm lymphedema decreases the incidence of erysipelas. Lymphology 2016; 49:85–92.
18. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 2013; 46:1–11.
19. Brorson H, Svensson H. Complete reduction of lymphoedema of the arm by liposuction after breast cancer. Scand J Plast Reconstr Surg Hand Surg 1997; 31:137–143.
20. Brorson H, Ohlin K, Olsson G, Nilsson M. Adipose tissue dominates chronic arm lymphedema following breast cancer: An analysis using volume rendered CT images. Lymphat Res Biol 2006; 4:199–210.
21. Brorson H, Ohlin K, Olsson G, Karlsson MK. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol 2009; 7:3–10.
22. Tassenoy A, De Strjicker D, Adriaenssens N, Lievens P. The use of noninvasive imaging techniques in the assessment of secondary lymphedema tissue changes as part of staging lymphedema. Lymphat Res Biol 2016; 14:127–133.
23. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Res Imaging 2011; 34:729–749.
24. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984; 153:189–194.
25. Reeder SB, Wen Z, Yu H, Pineda AR, Gold GE, Markl M, Pclc NJ. Multicoil Dixon chemical species separation with an iterative least-squares estimation method. Magn Reson Med 2004; 51:35–45.
26. Hernando D, Sharma SD, Aliyari Ghasabeh M, Alvis BD, Arora SS, Hamilton G, Pan L, Shaffer JM, Sofue K, Szeverenyi NM, Welch EB, Yuan Q, Bashir MR, Kamel IR, Rice MJ, Sirlin CB, Yokoo T, Reeder SB. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med 2017; 77:1516–1524.
27. Hines CD, Agni R, Roen C, Rowland I, Hernando D, Sharma SD, Aliyari Ghasabeh M, Alvis BD, Arora SS, Hamilton G, Pan L, Shaffer JM, Sofue K, Szeverenyi NM, Welch EB, Yuan Q, Bashir MR, Kamel IR, Rice MJ, Sirlin CB, Yokoo T, Reeder SB. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med 2017; 77:1516–1524.
28. Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, Motosugi U, Sharma SD, Munoz del Rio A, Fernandez L, Reeder SB. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology 2015; 62:1444–1455.
29. Peterson P, Romu T, Brorson H, Dahlqvist Leinhard O, Reeder SB. Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Res Imaging 2012; 35:844–851.
30. Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, Motosugi U, Sharma SD, Munoz del Rio A, Fernandez L, Reeder SB. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology 2015; 62:1444–1455.
31. Peterson P, Romu T, Brorson H, Dahlqvist Leinhard O, Reeder SB. Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Res Imaging 2012; 35:844–851.
32. Yu H, Shimakawa A, Hines CD, McKenzie CA, Hamilton G, Sirlin CB, Brittain JH, Reeder SB. Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med 2011; 66:199–206.

33. Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008; 60:1122–1134.

34. Case TC, Unger E, Bernas MJ, Witte MH, Witte CL, McNeill G, Crandall C, Crandall R. Lymphatic imaging in experimental filariasis using magnetic resonance. Invest Radiol 1992; 27:293–297.

35. Lahtinen T, Seppala J, Viren T, Johansson K. Experimental and analytical comparisons of tissue dielectric constant (TDC) and bioimpedance spectroscopy (BIS) in assessment of early arm lymphedema in breast cancer patients after axillary surgery and radiotherapy. Lymphat Res Biol 2015; 13:176–185.

36. Czerniec SA, Ward LC, Kilbreath SL. Assessment of breast cancer-related lymphedema: A comparison of moisture meter and spot bioimpedance measurement. Lymphat Res Biol 2015; 13:10–19.

37. Baum T, Cordes C, Dieckmeyer M, Ruschke S, Franz D, Hauner H, Kirschke JS, Karampinos DC. MR-based assessment of body fat distribution and characteristics. Eur J Radiol 2016; 85:1512–1518.

38. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425–432.

39. Lago F, Dieguez C, Gomez-Reino J, Guallillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18:313–325.

40. Rosen ED. The molecular control of adipogenesis, with special reference to lymphatic pathology. Ann N Y Acad Sci 2002; 979:143–158 discussion 188–196.

41. Gallagher D, Proenca R, MaffeI M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425–432.

42. Boettcher M, Machann J, Stefan N, Thamer C, Haring HU, Claussen CD, Frische A, Schick F. Intermuscular adipose tissue (IMAT): Association with other adipose tissue compartments and insulin sensitivity. J Magn Reson Imaging 2009; 29:1340–1345.

43. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Meyer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH. Health, Ageing, and Body. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 2009; 90:1579–1585.

44. Beasley LE, Koster A, Newman AB, Javadi MK, Ferrucci L, Kritchevsky SB, Kuller LH, Pahor M, Schaap LA, Visser M, Rubin SM, Goodpaster BH, Harris TB; Health ABC Study. Inflammation and race and gender differences in computerized tomography–measured adipose depots. Obesity (Silver Spring) 2009; 17:1062–1069.

45. Zoico E, Rossi A, Di Francesco V, Sepe A, Olioso D, Pizzini F, Fantin F, Bosello O, Cominacini L, Harris TB, Zamboni M. Adipose tissue infiltration in skeletal muscle of healthy elderly men: Relationships with body composition, insulin resistance, and inflammation at the systemic and tissue level. J Gerontol A Biol Sci Med Sci 2010; 65:295–299.

46. Elliott J, Pedler A, Kenardy J, Galloway G, Juli G, Sterling M. The temporal development of fatty infiltrates in the neck muscles following whiplash injury: An association with pain and posttraumatic stress. PLoS One 2011; 6:e21194.

47. Gerdle B, Forsgren MF, Bengtsson A, Leinhard OD, Soren B, Karlsson A, Brandejsky V, Lund E, Lundberg P. Decreased muscle concentrations of ATP and PCR in the quadriceps muscle of fibromyalgia patients—a 31P-MRS study. Eur J Pain 2013; 17:1205–1215.

Address correspondence to:
Mattias Hoffner, MD
Department of Surgery
Blekinge Hospital
371 85 Karlskrona
Sweden

E-mail: mattias.hoffner@med.lu.se